Loading stock data…
$7.35
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.70M↑ | $954,000↓ | $1.07M↑ | $749,000↑ | $719,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$41.72M↓ | -$30.16M↑ | -$39.35M↓ | -$28.41M↓ | -$25.25M |
| Net Income | -$32.52M↓ | -$29.78M↑ | -$544.81M↓ | -$61.07M↓ | -$27.73M |
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation o...